PMs indicate I may have caused some confusion with
Post# of 7791
My estimate was .002+ .
IMO, it depends a lot on who the RecoveryRx Partners are. If we had a quartet of top tier Medical Products Distributors, example, McKesson, Cardinal, AmerisourceBergen, Schein, then .02 would be in play.
With mid sized companies like STADA, if one can consider $3 billion a year mid sized, I speculate a doubling of price on announcement, rising from there as revenue starts flowing.
The RecoveryRx Distributor PR could also have the effect of more confidence in the ActiPatch OEM/Licensing Partners, resulting in more SP appreciation.
Enjoy the Ride and remember that the MMs will jerk things to the left or right to make their money until substantial news with names hits. The volume that this news creates makes their manipulation too risky and actual Supply/Demand Trading kicks in.